SAN FRANCISCO, CA--(Marketwired - Jan 29, 2014) - Vista Partners announced today that it has initiated coverage on CytoSorbents Corporation (OTCQB: CTSO) ("The Company," or "CTSO"); with a twelve month price target of $0.50. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company is on the "ground floor" of commercialization and positioned to potentially create significant value with their approved product, CytoSorb®, which has the potential to revolutionize critical care medicine; save lives, and reduce cost. CytoSorb® and the other products in the Company's pipeline may have significant upside, considering the massive markets they seek to address. The Company has received validation of their technology from many large organizations including: Biocon, DARPA, U.S. Army, U.S. Air Force, NIH/NHLBI, scientific advisors & analysts. The Company enjoys a unique, high margin product and pipeline with little to no current competition."
To download a FREE copy of the CytoSorbents Corporation research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.